HHS interim rule means tougher penalties for HIPAA violations
This article was originally published in SRA
The US Department of Health and Human Services has put out for comment an interim final rule that would impose tougher penalties for violating federal provisions designed to prevent the misuse of personal health information1. Under the rule, penalties could be imposed on “covered entities” (ie health plans, healthcare providers or healthcare clearinghouses), including clinical investigators. The rule will take effect on 30 November, with the comment period running until 29 December.
You may also be interested in...
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.
Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.